Source comparison
Thymosin Alpha-1 Chronic Infection Research: Study Type Comparison
RCT. Hepatitis B (Journal of Viral Hepatitis, 2016) 294 HBeAg-positive chronic HBV patients HBeAg seroconversion at 24 weeks 1.6 mg SC twice weekly × 24 weeks + lamivudine 25% seroconversion 38% seroconversion Clinically meaningful 13-point absolute difference
This comparison does not assign a generated winner or score.
- RCT. Hepatitis B (Journal of Viral Hepatitis, 2016)
- 294 HBeAg-positive chronic HBV patients
- HBeAg seroconversion at 24 weeks
- 1.6 mg SC twice weekly × 24 weeks + lamivudine
- 25% seroconversion
- 38% seroconversion
- Clinically meaningful 13-point absolute difference; cost-benefit depends on regional drug pricing but mechanistically sound
- Phase III. Hepatitis C (University of Naples, 2012)
- Genotype 1 HCV patients with high viral load
- Sustained virological response (SVR) at 24 weeks post-treatment
- 1.6 mg SC twice weekly + pegIFN + ribavirin
- 42% SVR
- 58% SVR
- 16-point SVR improvement justifies adjunctive use in treatment-experienced or high-VL patients where standard therapy underperforms
- Multicenter RCT. Severe Sepsis (Critical Care Medicine, 2019)
- 782 ICU patients with sepsis and lymphopenia (<800 cells/μL)
- 28-day all-cause mortality
- 1.6 mg IV daily × 5 days
- 34% mortality
- 26% mortality
- 8-point absolute mortality reduction (NNT=12) is clinically significant; benefit concentrated in lymphopenic subgroup
- Meta-Analysis. HIV/HBV Co-Infection (Antiviral Therapy, 2020)
- 6 trials, 438 co-infected patients
- CD4+ count increase at 48 weeks
- Varied (0.9–1.6 mg SC 2×/week)
- +42 cells/μL mean
- +89 cells/μL mean
- Modest but consistent CD4 gain in population where immune recovery is paramount; not a replacement for ART but defensible adjunct